JFrog Ltd. provides DevOps platform to achieve continuous software release management platform enabling organizations to deliver software updates across any system in the United States. Its platform acts as a bridge between software development and deployment, which enables organizations to build and release software faster and securely. The company's products include JFrog Artifactory, a package repository that allows teams and organizations to store, update, and manage their software packages at any scale; JFrog Pipelines, an integration/continuous delivery tool for automating and orchestrating the movement of software packages; JFrog Xray, which scan JFrog Artifactory to secure all packages stored in it; JFrog Distribution that provides software package distribution with enterprise-grade performance; JFrog Artifactory Edge that utilizes and leverages metadata from JFrog Artifactory to facilitate the transfer of the incremental changes in software packages from their previous versions; JFrog Mission Control, a platform control panel that provides a view of moving pieces of an organization's CSRM workflow; and JFrog Insight, a DevOps intelligence tool. Its products also comprise JFrog Pro, JFrog Pro X, JFrog Enterprise, JFrog Pro Team, and JFrog Enterprise Plus products that offer ongoing updates, upgrades, and bug fixes, as well as cluster configuration, multi-site replication, and SLA support. The company serves technology, financial services, retail, healthcare, and telecommunications organizations. JFrog Ltd. was incorporated in 2008 and is headquartered in Sunnyvale, California.
IPO Year: 2020
Exchange: NASDAQ
Website: jfrog.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/11/2025 | $40.00 | Outperform | Raymond James |
9/5/2024 | $30.00 → $33.00 | Buy | Needham |
8/27/2024 | $32.00 | Outperform | Robert W. Baird |
8/8/2024 | Outperform → Perform | Oppenheimer | |
7/24/2024 | $50.00 | Buy | TD Cowen |
6/26/2024 | $50.00 | Overweight | Barclays |
5/22/2024 | $45.00 | Outperform | FBN Securities |
5/22/2024 | $41.00 | Buy | UBS |
3/19/2024 | $52.00 | Overweight | KeyBanc Capital Markets |
12/21/2023 | $32.00 → $42.00 | Equal-Weight → Overweight | Morgan Stanley |